Wed, Jul 30, 2014, 2:23 PM EDT - U.S. Markets close in 1 hr 37 mins

Recent

% | $
Click the to save as a favorite.

ONYX Pharmaceuticals, Inc. Message Board

  • johnpapas893 johnpapas893 Oct 11, 2012 8:49 AM Flag

    Canaccord Genuity assumes coverage on Onyx Pharmaceuticals (NASDAQ: ONXX) with a Buy. PT $105.00.

    UPDATE: Canaccord Genuity Assumes Onyx Pharmaceuticals (ONXX) at Buy
    6:48 AM ET, 10/11/2012 - Street Insider

    (Updated - October 11, 20128:36 AM EDT)

    Canaccord Genuity assumes coverage on Onyx Pharmaceuticals (NASDAQ: ONXX) with a Buy. PT $105.00.

    "The key value driver is Kyprolis, a wholly-owned proteasome inhibitor (PI), recently approved in the U.S. for relapsed/refractory multiple myeloma (RRMM)," analyst Salveen Richter comments, "Our physician feedback suggests Kyprolis is seeing rapid uptake in its ~11 weeks since launch, with decent off-label administration (combination therapy; earlier-line setting and higher doses). We model for Kyprolis peak sales of $2.1B in 2020, with $10.4M in Q3 and $39.7M in 2012 (vs. consensus of $5.5M and $22.2M, respectively). Nexavar ($1B in FY12E revenue) and Stivarga, partnered with Bayer, provide a solid stream of revenue, with upside potential. The next key catalysts are Q3 EPS, P3 DECISION data (Nexavar in thyroid cancer in Q4), P1/2 oprozomib data at ASH (Dec. 9-11) and ASPIRE data (see below; interim analysis in H1/13)."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "We model for Kyprolis peak sales of $2.1B in 2020, with $10.4M in Q3 and $39.7M in 2012 (vs. consensus of $5.5M and $22.2M, respectively). Nexavar ($1B in FY12E revenue) and Stivarga, partnered with Bayer, provide a solid stream of revenue, with upside potential. The next key catalysts are Q3 EPS, P3 DECISION data (Nexavar in thyroid cancer in Q4), P1/2 oprozomib data at ASH (Dec. 9-11) and ASPIRE data (see below; interim analysis in H1/13)."

      Hard to accept that if all of this happens the SP is constrained as they project. What is missing?

      • 1 Reply to nidan7500
      • If I recall correctly, when Nexavar liver trials were unexpectedly halted early on positive results, stock climbed from $13 to $26 in a single day on 60+ mil volume. This was around Feb. 2007. By Dec. 2007 it had reached around $55+ as potential for Nexavar became more clearer.

        In the coming days as revenue potential from Kyprolis is confirmed, this will go higher.

        Sentiment: Strong Buy

 
ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.